The conditions for listing of CELLINK on Nasdaq Stockholm have been fulfilled

CELLINK AB (publ) (“CELLINK” or the “Company”) (CELLINK is listed on Nasdaq First North Growth Market under CLNK B) announced on April 3, 2020, that the company had received approval for a listing on Nasdaq Stockholm, following the fulfilment of customary conditions. CELLINK has today received confirmation that the conditions have been fulfilled and accordingly, CELLINK’s first day of trading on Nasdaq Stockholm’s main market is April 20, 2020. The last day of trading on Nasdaq First North Growth Market is April 17, 2020.

For further information, please contact:

Erik Gatenholm, CEO                                                                               Gusten Danielsson, CFO

Phone: EU +46 73 267 00 00                                                                 Phone: +46 70 991 86 04
US +1 (650) 515 5566                                                                             US +1 (857) 332 2138

Email: [email protected]                                                                             Email: [email protected]

The information was sent for publication, through the agency of the contact persons set out above, on April 15, 2020, at 17:20 CEST.

About CELLINK

CELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. We focus on three application areas including bioprinting, analysis and liquid handling & bioprocessing to be able to deliver a complete solution in our life science niche. We target to develop and commercialize cell culture technologies, enabling researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 with installations in more than 55 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK B. Erik Penser Bank AB is the Company’s certified adviser, available by phone at +46 846 383 00 and by email at: [email protected]

Latest press releases
March 22, 2020RegulatoryUpdate regarding COVID-19
November 14, 2019Annual Report 2018/2019